=== Population Extract 1 (Patients) ===
η με FISH, NGS, PCR) : Larotrect
MSI-H, dMMR (ανίχνευση με IHC, NGS, PCR): Pembroli
• TMB-H (>10mut/Mb, ανίχνευση με NGS): Pembrolizum
RET Fusion (ανίχνευση με NGS): Selpercatinib (FDA app
tinib ή Entrectini
izumab , Dostarl
mab
proval only)
ib
limab (Dostarlim
mab 500mg κάθε
negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients:
First results of Intergroup Trial INT 0102 (abstract). Proc Am Soc Clin Oncol 1998; 17:1a.
50.Piccart, MJ, Di Leo, A, Beauduin, M et. al. Phase III trial comparing two dose levels of epirubicin combined
with cyclophosphamide

=== Population Extract 2 (Patients) ===
: Pembroli
• TMB-H (>10mut/Mb, ανίχνευση με NGS): Pembrolizum
RET Fusion (ανίχνευση με NGS): Selpercatinib (FDA app
tinib ή Entrectini
izumab , Dostarl
mab
proval only)
ib
limab (Dostarlim
mab 500mg κάθε
negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients:
First results of Intergroup Trial INT 0102 (abstract). Proc Am Soc Clin Oncol 1998; 17:1a.
50.Piccart, MJ, Di Leo, A, Beauduin, M et. al. Phase III trial comparing two dose levels of epirubicin combined
with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive br

=== Population Extract 3 (Patients) ===
ated analysis of three phase 1-2 trials. Lancet Oncol. 2020 Feb;21(2):271-282. doi:
10.1016/S1470-2045(19)30691-6,PMID: 31838007; PMCID: PMC7461630.
110. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried
M, Diaz LA Jr et al, Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite
Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin
Oncol. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, O

=== Population Extract 4 (Patients) ===
col. 2020 Jan 1;38(1):1-10. doi: 10.1200/JCO.19.02105. PMID: 31682550; PMCID: PMC8184060.
111. Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, Takeda M, Ohe Y, Khan S, Ohashi K,
Soldatenkova V, Szymczak S, Sullivan L, Wright J, Drilon A. Tumour-agnostic efficacy and safety of
selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours
(LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022 Oct;23(10):1261-1273. doi: a)
Στάδια IA και ΙΒ σε όγκους χαμηλής διαφοροποίησης (grade 3)
b)
Στάδια ΙC-IV
ΘΕΡΑΠΕΙΑ ΣΥΝΤΗΡΗΣΗΣ (MAINTENANCE) Paclitaxel

=== Population Extract 5 (Patients) ===
gestrolacetate
iii. Medroxyprogesteroneacetate
iv. GnRHanalogs
Meri
expre
Onco
ic-Bernstam F, Ma
essing solid tumo
ology Annual Mee
akker V, Oaknin A, et al. Efficacy and safety of trastuzu
ors: DESTINYPanTumor02 interim results. Presente
eting; June 2–6, 2023; Chicago, Illinois.
umab deruxtecan in patients with HER2-
ed at the American Society of Clinical του ανθρώπινου θηλώματος (HPV). Ο εμβολιασμός, έναντι υποτύπων του ιού HPV, δεν αναιρεί τις ισχύουσες
Το θεραπευτικό πλάνο που ακολουθείται σε ασθενείς πρώιμου σταδίου κατά FIGO (IA, IB1 και ΙΙΑ ≤4 cm) [3]
i. είτε ριζική υστερεκτομή (με ή χωρίς adju

=== Population Extract 6 (Patients) ===
V, Sorafenib in advanced hepatocellular carcinoma N Engl J Med. 2008 Jul
2. Martin RC, Jarnagin WR. Randomized clinical trials in hepatocellular carcinoma and biliary cancer. Surg
Oncol Clin N Am 2002;11:193, x.
33.Kudo M, Finn RS, Qin S et al; Lenvatinib versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar
34.Bruix J, Qin S, Merle P, Granito A et al ; RESORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-

=== Population Extract 7 (Patients) ===
2;11:193, x.
33.Kudo M, Finn RS, Qin S et al; Lenvatinib versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar
34.Bruix J, Qin S, Merle P, Granito A et al ; RESORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepat

=== Population Extract 8 (Patients) ===
ORCE Investigators. Regorafenib for patients with
hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-
blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63
36.Zhu AX, Kang YK, Yen CJ ae al , ; REACH-2 study investigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
rand

=== Population Extract 9 (Patients) ===
Jan 7;389(10064):56-66. Epub 2016 Dec 6
35.Abou-Alfa GK, Meyer T, Cheng AL et al ; Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54-63
36.Zhu AX, Kang YK, Yen CJ ae al , ; REACH-2 study investigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296.
37.El-Khoueiry AB, Sangro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(C

=== Population Extract 10 (Patients) ===
stigators. Ramucirumab after sorafenib in patients
with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Feb;20(2):282-296.
37.El-Khoueiry AB, Sangro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet.
2017 Jun 24;389(10088):2492-2502.
38.Zhu AX, Finn RS, Edeline J et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced
hepatocellular car

=== Population Extract 11 (Patients) ===
gro B, Yau T et al; Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet.
2017 Jun 24;389(10088):2492-2502.
38.Zhu AX, Finn RS, Edeline J et al; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced
hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-
label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940-952
39.Qin S., Bai Y., Lim HY., Randomized, multicentre, open label study of oxaliplatin plus 5FU/leucovorin
versus doxorubicin as pa

=== Population Extract 12 (Patients) ===
ular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-
label phase 2 trial. Lancet Oncol. 2018 Jul;19(7):940-952
39.Qin S., Bai Y., Lim HY., Randomized, multicentre, open label study of oxaliplatin plus 5FU/leucovorin
versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma form
Asia, J. Clin. Oncol.2013;31:3501-3508
Διπλασιασμός των ανάλογων σωματοστατίνης ή συνδυασμός με τελοτριστάτη (TELECAST study) ή συνδυασμός
με ιντερφερόνη-α (5 x 10 U sc).
PRRT ή τοπική θεραπεία ηπατικών μεταστάσεων
( χημειοθεραπεία ή everolimus εκτός ένδε

=== Population Extract 13 (Patients) ===
Bajorin, M.D., J. Witjes, M.D., Gschwend et al: Adjuvant Nivolumab versus Placebo in Muscle-Invasive
Urothelial Carcinoma. N Engl J Med 2021; 384:2102-2114
3. Apolo AB, Infante JR, Hamid O, et al: Safety, clinical activity, and PD-L1 expression of avelumab
(MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the
JAVELIN Solid Tumor phase Ib trial. JCO Abstract Ε1ν. δεIpίξiεlιiςm: Σuτmάaδbια ΙΙb, IIc και ΙΙΙ (κατά AJCC)
Η έγκριση του είναι σε δόση 10mg/kgx4 δόσεις ανά 3 εβδομάδες και μετά αναμνηστικές δόσεις ανά 3 μήνες έως
32 .έ τNη,i vσoε lαuσmθaενbε ίς σταδίο

=== Population Extract 14 (Patients) ===
survival, high-risk features, and adjuvant chemoradiotherapy outcomes. Head & neck 2017;39(5):881-
4. Schmults CD. High-risk cutaneous squamous cell carcinoma: a practical guide for patient management.
Berlin, Germany: Springer-Verlag Berlin Heidelberg 2016.
5. Treatment patterns and outcomes among patients with advanced cutaneous squamous cell carcinoma
(CSCC) in a US community oncology setting. ASCO Annual meeting; 2019.
6. Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and
metastatic disease. American journal of clinical dermatology 2016;17(5):491-508.

=== Population Extract 15 (Patients) ===
08. doi: 10.1007/s40257-
016-0207-3 [published Online First: 2016/07/01]
18. AssociazioneItaliana di Oncologia Medica (AIOM). LineeGuidaAIOM 2018 TUMORICUTANEINON
MELANOMA-Carcinoma squamocellularecutaneo, 2018.
21. Primary analysis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with
locally advanced cutaneous squamous cell carcinoma (laCSCC). ASCO Annual Meeting; 2019
22. Migden MR, Khushalani N, Chang A. Primary Analysis of Phase 2 results of Cemiplimab, a human
monoclonal anti-PD-1, in patients with locally advanced cutaneous squamous cell carcinoma 2019
American

=== Population Extract 16 (Patients) ===
sis of Phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with
locally advanced cutaneous squamous cell carcinoma (laCSCC). ASCO Annual Meeting; 2019
22. Migden MR, Khushalani N, Chang A. Primary Analysis of Phase 2 results of Cemiplimab, a human
monoclonal anti-PD-1, in patients with locally advanced cutaneous squamous cell carcinoma 2019
American Society of Clinical Oncology Annual Meeting. Chicago, Illinois, 2019.
Το βασικοκυτταρικό καρκίνωμα (basalcellcarcinoma, BCC) αντιπροσωπεύει περίπου το 80% όλων των μη
μελανοκυτταρικών καρκίνων του δέρματος [1]. Τα BCCs γενικά ανα

=== Population Extract 17 (Patients) ===
λαξη σε ότι αφορά τους >75 ετών για τους οποίους τα δεδομένα είναι
Συστήνεται η χρήση κάποιου εργαλείου πρόβλεψης της τοξικότητας από τη χημειοθεραπεία, όπως το CARG
score (Cancer and Aging Research Group Chemo Toxicity Calculator) και το CRASH score (Chemotherapy
Risk Assessment Scale for High-Age Patients), τα οποία έχουν αναπτυχθεί ειδικά για ηλικιωμένους ασθενείς.
o
o
o
Τροποποίηση δόσεων ΧΜΘ με βάση το ρυθμό σπειραματικής διήθησης (GFR).
o
o
/pertuzumab
o
Προσοχή στη χορήγηση trastuzumab σε προϋπάρχουσα καρδιακή νόσο.
o
(IMR
o
o
o
Παρακολούθηση παρεγκεφαλιδικής λειτουργίας κατά τη χορήγηση υψηλών

=== Population Extract 18 (Patients) ===
th cancer, especially that attributable to cancer
treatment. Health Technol Assess 2007;11:1-202.
5. Ludwig H, Van Belle S, Barrett-Lee, et al The European Cancer Anaemia Survey (ECAS): a large,
multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple m

=== Population Extract 19 (Patients) ===
Cancer Anaemia Survey (ECAS): a large,
multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewoo

=== Population Extract 20 (Patients) ===
aemia in
cancer patients. Eur J Cancer 2004;40:2293-2306.
6. Jabbour E, Kantarjian HM, Koller C, Taher A Red blood cell transfusions and iron overload in the
treatment of patients with myelodysplastic syndromes. Cancer 2008;112:1089-1095.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and
lymphoma: findings of the European Cander Anaemia Survey. Eur J Haematol 2006;77:378-386.
8.  (last accessed 8 May 2009).
9. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue and long-term outcome.
Oncology 2005;69 Suppl 2:2-7.
αρχική εκτίμηση και η περι

=== Population Extract 21 (Patients) ===
ών, με εφάνιση DVT, χωρίς παράγοντες κινδύνου, ενδείκν
κλινικοεργαστηριακός και απεικονιστικός έλεγχος (CT scan) για διάγνωση κακοήθειας. Ο ίδ
D-dimers ή πρώϊμη υποτροπή της φλεβοθρόμβωσης, παράλληλα με τον έλεγχο συνδρόμων υπε
(2C).
ΣΤ. THE KHORANA MODEL FOR EVALUATION OF THROMBOSIS RISK IN CANCER PATIENTS
Πίνακας 1. Predictive model for chemotherapy-associated venous thromboembolism Site of cancer
Very high risk (stomach, pancreas) 2
High risk (lung, lymphoma, gynaecological, bladder, testicular, renal) 1
Pre-chemotherapeutic platelet count ≥350,000 /microL 1
Haemoglobin concentration <10 g/dl or us

=== Population Extract 22 (Patients) ===
, The revised
International Association for the Study of Pain definition of pain: concepts, challenges, and
compromises,PAIN: September 2020 - Volume 161 - Issue 9 - p 1976-1982.
M. Fallon, R. Giusti, F. Aielli, P. Hoskin, R. Rolke, M. Sharma & C. I. Ripamonti,
2. Management of Cancer
Pain in Adult Patients: ESMO Clinical Practice Guidelines, Ann Oncol (2018) 29 (Suppl 4): iv166–iv191.
Grisell Vargas-Schaffer Can Fam
Physician
3. , Is the WHO analgesic ladder still valid? Twenty-four years of experience,
. 2010 Jun; 56(6): 514–517
4. Khanna I, Pillarisetti S, Buprenorphine – an attractive opioid with

=== Population Extract 23 (Patients) ===
rience and the role of premedication dental evaluation
in prevention. Oral Surg Oral Med Oral Pathol Oral Radiol. 125:440-445. doi:
10.1016/j.oooo.2018.02.003.
3. Schiodt M, Vadhan-Raj S, Chambers MS, et al (2018). A multicenter case registry study on medication-
related osteonecrosis of the jaw in patients with advanced cancer. Support Care Cancer 26: 1905-1915,
Doi:10.1007/s00520-017-4003-2.
4. Nicolatou-Galitis, O, Schiodt M, Mendes RA, et al (2019b). Medication-related osteonecrosis of the jaw:
definition and best practice for prevention, diagnosis and management. Oral Surg Oral Med Oral Pathol
Or

=== Population Extract 24 (Patients) ===
latou-Galitis O, Kouri M, Papadopoulou E, et al (2019a). Osteonecrosis of the jaw related to non-
antiresorptive medications: A systematic review. Support Care Cancer 27:383-394, Doi:10.1007/s00520-
018-4501-x.
6. Fusco V, et al (2022). One changing and challenging scenario: the treatment of cancer patients with bone
metastasis by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the
risk of medication-related osteonecrosis of he jaw (MRONJ). Supportive Care in Cancer,
doi.org/10.1007/s00520-022-06982-y.
7. Galiti D, Karayianni A, Tsiklakis K, Psyrri A. Medication Re

=== Population Extract 25 (Patients) ===
o-2022-0005.
8. Galiti D, Karayianni A, Tsiklakis K, Psyrri A. Cone Beam Computed Tomography (CBCT) is Superior to
Orthopantomogram (OPG) in Interpreting the Imaging Characteristics of Medication-Related
Osteonecrosis of the Jaw (MRONJ and More Stage-Sensitive: A Prospective Assessment in 98 Cancer
Patients. World J Surg Surgical Res. 2021; 4: 1335.
9. Otto S, et al (2021). Infection as an important factor in Medication-Related Osteonecrosis of the Jaw
(MRONJ). Medicina 57:463.
10. Nicolatou-Galitis O, Papadopoulou E, Vardas E, et al (2020) Alveolar bone histological necrosis observed
prior to extract

=== Population Extract 26 (Patients) ===
J Surg Surgical Res. 2021; 4: 1335.
9. Otto S, et al (2021). Infection as an important factor in Medication-Related Osteonecrosis of the Jaw
(MRONJ). Medicina 57:463.
10. Nicolatou-Galitis O, Papadopoulou E, Vardas E, et al (2020) Alveolar bone histological necrosis observed
prior to extractions in patients, who receive bone-targeting agents. Oral Dis 26: 955-966.
11. Ristow O, et al (2021a). Wound closure and alveoloplasty after preventive tooth extractions in patients
with antiresorptive intake-A randomized pilot study. Oral Diseases 27:532-546.
12. Ristow O, et al (2021b). Diagnostic accuracy compa

=== Population Extract 27 (Patients) ===
10. Nicolatou-Galitis O, Papadopoulou E, Vardas E, et al (2020) Alveolar bone histological necrosis observed
prior to extractions in patients, who receive bone-targeting agents. Oral Dis 26: 955-966.
11. Ristow O, et al (2021a). Wound closure and alveoloplasty after preventive tooth extractions in patients
with antiresorptive intake-A randomized pilot study. Oral Diseases 27:532-546.
12. Ristow O, et al (2021b). Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone
changes before tooth extractions in patients with antiresorptive intake. Oral Diseases, 2021:00:1-11, 7
October 2

=== Population Extract 28 (Patients) ===
ound closure and alveoloplasty after preventive tooth extractions in patients
with antiresorptive intake-A randomized pilot study. Oral Diseases 27:532-546.
12. Ristow O, et al (2021b). Diagnostic accuracy comparing OPG and CBCT in the detection of non-vital bone
changes before tooth extractions in patients with antiresorptive intake. Oral Diseases, 2021:00:1-11, 7
October 2021.
13. Otto S, Pautke C, Van den Wyngaert T, et al (2018). Medication-related osteonecrosis of the jaw:
Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment
Reviews 69:177-187.
14. Fu

=== Population Extract 29 (Patients) ===
CBCT in the detection of non-vital bone
changes before tooth extractions in patients with antiresorptive intake. Oral Diseases, 2021:00:1-11, 7
October 2021.
13. Otto S, Pautke C, Van den Wyngaert T, et al (2018). Medication-related osteonecrosis of the jaw:
Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treatment
Reviews 69:177-187.
14. Fusco V, Santini D, Campisi G, et al (2020). Comment on Medication-Related Osteonecrosis of the Jaw:
MASCC/ISOO/ASCO Clinical Practice Guideline Summary. JCO Oncol Pract 16:142-145, doi:
10.1200/JOP.19.00645.
15. Ristow O, Rü

=== Population Extract 30 (Patients) ===
acos VE. Diagnostic criteria for the classification of cancer-associated
weight loss. J ClinOncol. 2015 Jan 1;33(1):90-9. doi: 10.1200/JCO.2014.56.1894. Epub 2014 Nov 24.
4. Radbruch L, Elsner F, Trottenberg P, Strasser F, Fearon K. Clinical practice guidelines on cancer cachexia in
advanced cancer patients. Aachen, Department of Palliative Medicinen/European Palliative Care Research
Collaborative. 2010.
Oncologist.
ICD10, πρέπει να πληρούνται για να γίνει η διάγνωσή της (2).
Η yoga, ο βελονισμός, η μουσικοθεραπεία και άλλες θεραπευτικές προσεγγίσεις, αν και δεν έχουν αποδεδειγμένο
Η χρήση ψυχοδιεγερτ

=== Population Extract 31 (Patients) ===
oto Y, Kaneishi K, Odagiri T, Sakurai H, Katayama H,
Mori I, Yamada H, Watanabe H, Yokoyama T, Yamaguchi T, Nishi T, Shirado A, Hiramoto S, Watanabe T,
Kohara H, Shimoyama S, Aruga E, Baba M, Sumita K, Iwase S. Predictors of Responses to Corticosteroids
for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study.
J Pain Symptom Manage. 2016;52(1):64
0.5 – 1mg. Η χορήγησης μπορεί να επαναληφθεί σε διάστημα 45 – 60 λεπτών (4).
1. Kang JH, Shin SH, Bruera E. Comprehensive approaches to managing delirium in patients with advanced
cancer. Cancer Treat Rev 2013; 3

=== Population Extract 32 (Patients) ===
for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study.
J Pain Symptom Manage. 2016;52(1):64
0.5 – 1mg. Η χορήγησης μπορεί να επαναληφθεί σε διάστημα 45 – 60 λεπτών (4).
1. Kang JH, Shin SH, Bruera E. Comprehensive approaches to managing delirium in patients with advanced
cancer. Cancer Treat Rev 2013; 39: 105–112
2. Scottish Partnership for Palliative Care. Scottish Palliative Care Guidelines – Delirium. Scotland: NHS
Scotland, Healthcare Improvement Scotland 2014
3. Lipowski ZJ Delirium (acute confusional states).JAMA. 1987;258(13):1789.
4. Massie MJ

=== Population Extract 33 (Patients) ===
2
2. Scottish Partnership for Palliative Care. Scottish Palliative Care Guidelines – Delirium. Scotland: NHS
Scotland, Healthcare Improvement Scotland 2014
3. Lipowski ZJ Delirium (acute confusional states).JAMA. 1987;258(13):1789.
4. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983; 140:1048.
ασθενει�ς υπο� αγωγη� με PD-1 inhibitors, ενδε�χεται μα�λιστα να βελτιω�νουν την επιβι�ωση αντι�στοιχων
χορη�γηση του PCV20 (με την κατα�λληλη χρονικη� απο�σταση αν ε�χει προηγηθει� εμβολιασμο�ς με τα PCV13
και/ η� PPSV23).
απο� το 2023 διατι�θεται και στην Ελλα�δα

=== Population Extract 34 (Patients) ===
il M, Fourcade A, Blot E, et al. Cisplatin alone or combined with gemcitabine in carcinomas of
Row 9: unknown primary: Results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012;48:721–727.
Row 10: 37. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with
Row 11: carcinoma of an unknown primary site. Cancer. 2004;100:1257–1261.
Row 12: 38. Cassidy J, Clarke S, Diaz Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin
Row 13: compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colo

=== Population Extract 35 (Patients) ===
w 15: 39. Cheeseman SL, Joel SP, Chester JD, et al. A ‘modified de Gramont’ regimen of fluorouracil, alone and with
Row 16: oxaliplatin, for advanced colorectal cancer. Br J Cancer. 2002;87:393–399.
Row 17: 40. Demirci U, Coskun U, Karaca H, et al. Docetaxel and cisplatin in first line treatment of patients with
Row 18: unknown primary cancer: a multicenter study of the anatolian society of medical oncology. Asian Pac J
Row 19: Cancer Prev. 2014;15(4):1581–1584.
Row 20: 41. Yonemori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: Harb
Row 2: 33. Bria
Row

=== Population Extract 36 (Patients) ===
ocetaxel and cisplatin in first line treatment of patients with
Row 18: unknown primary cancer: a multicenter study of the anatolian society of medical oncology. Asian Pac J
Row 19: Cancer Prev. 2014;15(4):1581–1584.
Row 20: 41. Yonemori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: Harb
Row 2: 33. Bria
Row 3: A ph
Row 4: 34. Grec
Row 5: treat
Row 6: 35. Grec
Row 7: plus
Row 8: 36. Gros
Row 9: unkn
Row 10: 37. Poue
Row 11: carc
Row 12: 38. Cass
Row 13: com
Row 14: canc
Row 15: 39. Chee
Row 16: oxali
Row 17: 40. Dem
Row 18: unkn
Row 19: Canc
Row 20: 41.

=== Population Extract 37 (Patients) ===
8: ss-Goupil M, Fourcade A, Blot E, et al. Cisplatin alone or combined with gemcitabine in carcinomas of
Row 9: nown primary: Results of the randomised GEFCAPI 02 trial. Eur J Cancer. 2012;48:721–727.
Row 10: essel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with
Row 11: cinoma of an unknown primary site. Cancer. 2004;100:1257–1261.
Row 12: sidy J, Clarke S, Diaz Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin
Row 13: mpared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal
Row 1

=== Population Extract 38 (Patients) ===
;26:2006–2012.
Row 15: eseman SL, Joel SP, Chester JD, et al. A ‘modified de Gramont’ regimen of fluorouracil, alone and with
Row 16: iplatin, for advanced colorectal cancer. Br J Cancer. 2002;87:393–399.
Row 17: mirci U, Coskun U, Karaca H, et al. Docetaxel and cisplatin in first line treatment of patients with
Row 18: nown primary cancer: a multicenter study of the anatolian society of medical oncology. Asian Pac J
Row 19: cer Prev. 2014;15(4):1581–1584.
Row 20: emori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: 
Row 2: 42. Hainsworth JD, Spigel DR,

=== Population Extract 39 (Patients) ===
a H, et al. Docetaxel and cisplatin in first line treatment of patients with
Row 18: nown primary cancer: a multicenter study of the anatolian society of medical oncology. Asian Pac J
Row 19: cer Prev. 2014;15(4):1581–1584.
Row 20: emori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: 
Row 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H,

=== Population Extract 40 (Patients) ===
: cer Prev. 2014;15(4):1581–1584.
Row 20: emori K, Ando M, Yunokawa M, et al. Irinotecan plus carboplatin for patients with carcinoma of Row 1: 
Row 2: 42. Hainsworth JD, Spigel DR, Clark BL, et al. Paclitaxel/carboplatin/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficacy of a combination of docetaxel and cisplatin in
Row 3: patients with unknown primary cancer. Am J Clin Oncol. 2010;33:32–35.
Row 4: 45. Pointr

=== Population Extract 41 (Patients) ===
/etoposide versus
Row 3: gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a Row 1: review of 56 cases. Cancer 1987; 59:572.
Row 2: 44. Mukai H, Katsumata N, Ando M, et al. Safety and efficacy of a combination of docetaxel and cisplatin in
Row 3: patients with unknown primary cancer. Am J Clin Oncol. 2010;33:32–35.
Row 4: 45. Pointreau Y, Garaud P, Chapet S, et al. Randomized trial of induction chemotherapy with cisplatin and 5-
Row 5: fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101:498–506.
Row 6: 46. Ku

=== Population Extract 42 (Patients) ===
Randomized trial of induction chemotherapy with cisplatin and 5-
Row 5: fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101:498–506.
Row 6: 46. Kusaba H, Shibata Y, Arita S, et al. Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in
Row 7: patients with carcinoma of unknown primary site. Med Oncol. 2007;24:259–264.
Row 8: 47. Park YH, Ryoo BY, Choi SJ, et al. A phase II study of paclitaxel plus cisplatin chemotherapy in an
Row 9: unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol. 2004;34:681–685.
Row 10: 48.

=== Population Extract 43 (Patients) ===
et al. Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in
Row 7: patients with carcinoma of unknown primary site. Med Oncol. 2007;24:259–264.
Row 8: 47. Park YH, Ryoo BY, Choi SJ, et al. A phase II study of paclitaxel plus cisplatin chemotherapy in an
Row 9: unfavourable group of patients with cancer of unknown primary site. Jpn J Clin Oncol. 2004;34:681–685.
Row 10: 48. Pantheroudakis G, Briasoulis E, Kalofonos HP, et al. Docetaxel and carboplatin combination
Row 11: chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicenter Hellenic
Row 12: Cooper

=== Population Extract 44 (Patients) ===
boplatin combination
Row 11: chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicenter Hellenic
Row 12: Cooperative Oncology Group phase II study. Acta Oncol.
Row 13: 49. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel as front-line chemotherapy in patients with
Row 14: carcinoma of an unknown primary site. Cancer 2004; 100:1257.
Row 15: 50. Greco FA, Burris HA 3rd, Erland JB, et al. Carcinoma of unknown primary site. Cancer 2000; 89:2655.
Row 16: 51. Greco FA, Erland JB, Morrissey LH, et al. Carcinoma of unknown primary site: phase II trials with
Row

=== Population Extract 45 (Patients) ===
extrapulmonary neuroendocrine carcinomas.
Row 6: Pancreas 2010; 39:799.
Row 7: 60. Spigel DR, Hainsworth JD, Greco FA. Neuroendocrine carcinoma of unknown primary site. Semin Oncol
Row 8: 2009; 36:52
Row 9: 61. Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with
Row 10: liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and Row 1: Παράμετρος που εξετάζεται|Εργαλεία που χρησιμοποιούνται
Row 2: Λειτουργική κατάσταση|Activities of Daily Living (ADL) Instrumental Activities of Daily Living (IADL)
Row 3: Συνοδά νο

=== Population Extract 46 (Patients) ===
4: fluoxymesterone for the treatment of cancer anorexia/cachexia. J ClinOncol. 1999;17(10):3299.|
Row 5: |
Row 6: 15. Currow D, Temel JS, Abernethy A, Milanowski J, Friend J, Fearon KC. .ROMANA 3: a phase 3 safety extension|
Row 7: study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia.AnnOncol.|
Row 8: 2017;28(8):1949.| Row 1: |
Row 2: 1. Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, Schnipper HH, Lacchetti C, Ligibel JA,|
Row 3: Lyman GH, Ogaily MS, Pirl WF, Jacobsen PB, American Society of Clinical Oncology.|Lyman GH, Ogaily MS, Pirl WF, Jacobsen

=== Population Extract 47 (Patients) ===
Sakurai H, Katayama H,|
Row 12: |Mori I, Yamada H, Watanabe H, Yokoyama T, Yamaguchi T, Nishi T, Shirado A, Hiramoto S, Watanabe T,|
Row 13: |Kohara H, Shimoyama S, Aruga E, Baba M, Sumita K, Iwase S. Predictors of Responses to Corticosteroids|
Row 14: |for Cancer-Related Fatigue in Advanced Cancer Patients: A Multicenter, Prospective, Observational Study.| Row 1: 
Row 2: 
Row 3: 
Row 4: 
Row 5: 
Row 6: 
Row 7: 
Row 8: 
Row 9: 
Row 10:  Row 1: Scotland, Healthcare Improvement Scotland 2014
Row 2: 3. Lipowski ZJ Delirium (acute confusional states).JAMA. 1987;258(13):1789.
Row 3: 4. Massie MJ, Holland J

=== Population Extract 48 (Patients) ===
tudy.| Row 1: 
Row 2: 
Row 3: 
Row 4: 
Row 5: 
Row 6: 
Row 7: 
Row 8: 
Row 9: 
Row 10:  Row 1: Scotland, Healthcare Improvement Scotland 2014
Row 2: 3. Lipowski ZJ Delirium (acute confusional states).JAMA. 1987;258(13):1789.
Row 3: 4. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983; 140:1048.
Row 4: 5. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and
Row 5: lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.
Row 6: 6. Hui D, Frisbee-Hume S, Wilson A, et al.

=== Population Extract 49 (Patients) ===
):1789.
Row 3: 4. Massie MJ, Holland J, Glass E. Delirium in terminally ill cancer patients. Am J Psychiatry 1983; 140:1048.
Row 4: 5. Breitbart W, Marotta R, Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and
Row 5: lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.
Row 6: 6. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on
Row 7: Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8: Trial. JAMA 2017; 318:1047.
Row 9: 7. Boet

=== Population Extract 50 (Patients) ===
uble-blind trial of haloperidol, chlorpromazine, and
Row 5: lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry 1996; 153:231.
Row 6: 6. Hui D, Frisbee-Hume S, Wilson A, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on
Row 7: Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical
Row 8: Trial. JAMA 2017; 318:1047.
Row 9: 7. Boettger S, Jenewein J, Breitbart W. Haloperidol, risperidone, olanzapine and aripiprazole in the
Row 10: management of delirium: A comparison of efficacy, safety, and side effects. Pa

=== Population Extract 51 (Adults) ===
τα φάρμακα χορηγούνται και σε
ασθενείς με κλασσικό σάρκωμα Kaposi λόγω έλλειψης μελετών.
Βινορελμπίνη – C46, Kaposi
- Ναμπ-Πακλιταξέλη - C46, Kaposi
Πακλιταξέλη - C46, Kaposi
Πεγκυλιωμένη λιποσωμιακή δοξορουβικίνη - C46, Kaposi
1. Adjuvant chemotherapy for localisedresectable soft tissue sarcoma in adults. SarcomaMeta-
analysisCollaboration (SMAC). CochraneDatabaseSystRev. 2000;
C40, C40.0, C40.1, C40.2, C40.3, C40.8, C40.9, C41, C41.0, C41.1, C41.2, C41.3, C41.4, C41.8, C41.9
1. Cisplatin 100mg/m², IV + Doxorubicin 75mg/m², IV για 4 κύκλους και Doxorubicin 75mg/m², IV για 2
2. Σχήμα API-AI
Adriamyc

=== Population Extract 52 (Adults) ===
.24; 1.04, 95% CI 0.86-
αντιμετωπίζονται με Π.Δ.Ε., σε σύγκριση με εικονικό φάρμακο ( RR 1.67, 95% CI 1.35-2.06) [I].
1. Blanc B, Finch CA, Hallberg L, et al Nutritional anaemias. Report of a WHO Scientific Group. WHO Tech
Rep Ser 1968;405:1-40.
2. Groopman JE,Itri LM Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer
Inst 1999;91:1616-1634.
3. Mercadante S, Gebbia V, Marrazzo A, et al Anemia in cancer: pathophysiology and treatment. Cancer
Treat Rev 2000;26:303-311.
4. Wilson J, Yao GL, Raftery J, et al A systematic review and economic evaluation of epoetin alpha, epoetin

